

## **Quantom Biosciences' Ntensify™ Midi System Adopted by Bio-Manguinhos/Fiocruz Laboratory for Future Groundbreaking mRNA Vaccine Production in Latin America**

**Nivelles, Belgium – Thursday, March 7, 2024**

Quantom Biosciences S.A. (“Quantom”), part of Univercells S.A. is proud to announce its significant collaboration with the Institute of Technology on Immunobiologicals (Bio-Manguinhos/Fiocruz), Brazil's leading public health institute and vaccine manufacturer. This agreement is founded on Bio-Manguinhos' acquisition of Quantom's Ntensify™ Midi system in order to produce Brazil's first proprietary XBB COVID-19 vaccine at Bio-Manguinhos. Discussions are ongoing for the co-development of novel mRNA-based vaccines.

The Ntensify™ Midi is a GMP-grade mRNA production system introducing a novel approach to mRNA synthesis and purification. Its scalable design, construct-agnostic process, and automated production capabilities enable cost-effective, gram-scale batch production of high-quality mRNA as a Drug Substance.

Bio-Manguinhos/Fiocruz, one of Brazil's largest and globally recognized public laboratories, is renowned for its expertise in vaccine manufacturing. This includes being the world's largest producer of the yellow fever vaccine and the only Latin American laboratory certified by the World Health Organization (WHO) for this purpose. The adoption of the Ntensify™ Midi system at Bio-Manguinhos/Fiocruz marks a significant milestone for Quantom Biosciences, as it represents the first time a Latin American player builds up GMP mRNA production capabilities. This pivotal industrial validation of Quantom's innovative technology is further underscored by Bio-Manguinhos' extensive vaccine production capabilities and its esteemed global standing.

The partnership extends beyond equipment acquisition, as Univercells and Bio-Manguinhos/Fiocruz are actively discussing the co-development of novel mRNA-based vaccines, targeting diseases that have a global health impact. Further details will be provided in the near future.

José Castillo, CEO of Quantom Biosciences and CTO of Univercells, expressed his excitement for this new collaboration: "We are thrilled to see our Ntensify™ Midi system become a cornerstone in Bio-Manguinhos' vaccine production. This partnership not only validates our technology on an industrial scale but also aligns with our mission to contribute to global health initiatives and equitable vaccine access."

"The partnership with Quantom and the Ntensify™ Midi system was fundamental to accelerate our development process. We are very excited to get the first batches produced in our GMP area very soon", celebrates Patricia Neves, Scientific Leader of the RNA Bio-Manguinhos/Fiocruz Project.

### **About Bio-Manguinhos/Fiocruz**

The Institute of Technology in Immunobiologicals (Bio-Manguinhos) is the unit of the Oswaldo Cruz Foundation (Fiocruz) responsible for research, innovation, technological development and the production of vaccines, diagnostic kits and biopharmaceuticals aimed at primarily meeting the demands of national public health. Founded in 1976, Bio-Manguinhos has a prominent presence

on the international scene, not only through the export of surplus production to more than 70 countries but also through the exchange of experiences and information, technical-scientific events and partnerships with public and private institutions through Technology Transfer agreements, Partnerships for Productive Development (PDPs) and indigenous development projects, which contribute to expanding its portfolio, which has more than 40 products.

For more information, visit: [www.bio.fiocruz.br](http://www.bio.fiocruz.br)

### **About Quantom Biosciences**

Quantom Biosciences is reinventing mRNA production by developing an RNA Platform (Nfinity™) that encompasses DNA (Nplify™) and RNA (Ntensify™) manufacturing and formulation (Ncapsulate™), along with critical reagent supply, from small to larger scale, ideally for pre-clinical and clinical study or trial projects. We are a team of scientists, engineers and clinicians committed to solving some of the biggest DNA and RNA production challenges facing vaccines and therapeutics, by delivering greater access and autonomy to mRNA technology. Our facilities are strategically located in Belgium and France, in the heart of Europe, benefiting from an exceptional biotech ecosystem. Quantom Biosciences is part of [Univercells](#), a global life sciences Group with the mission of making biologics accessible to all".

[www.quantom.com](http://www.quantom.com)

### **Contact details**

#### **Quantom Biosciences**

José Castillo  
Chief Executive Officer  
[press@quantom.com](mailto:press@quantom.com)

#### **Univercells Media Relations**

Cécile Hissette  
VP Corporate Communications  
[c.hissette@univercells.com](mailto:c.hissette@univercells.com)  
+32.473.36.14.11

### **Disclosure Statement**

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified using forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.